Tarceva and all the rest

Genentech/OSI today announced US sales of Tarceva were up 1% compared to Q3 2006.  This does however include an usually large volume of product returns [which I guess means that they shipped product earlier, accounted for those revenues and now have to take them back for product that didn't actually sell].  Gross sales were up 12% compared to Q3′06, and OSIP/GENE reiterated their forecasts for annual sales of $855-$860m (up from $650m in 2006).

Q3 reporting season is only starting - I’ll update the spreadsheet when all the dust has settled.